Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

96.02 -0.10 (-0.10%)
Streaming Delayed Price Updated: 10:11 AM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merus N.V. - Common Shares

< Previous 1 2 3 4 Next >
News headline image
Halper Sadeh LLC Encourages CADE, THS, CMA, MRUS Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
From Merus N.V.
Via GlobeNewswire
News headline image
HALPER SADEH LLC ENCOURAGES MTSR, HOLX, MRUS SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
News headline image
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRO, EA, MRUS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA and MRUS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
MRUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Merus N.V. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
From Genmab A/S
Via Business Wire
News headline image
Merus to Present at the 2025 Wells Fargo Healthcare Conference
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
News headline image
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Merus N.V.
Via GlobeNewswire
News headline image
Merus N.V. Announces Pricing of Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
News headline image
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
News headline image
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Present at BofA Securities 2025 Health Care Conference
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.